Ingenuity Announces Significant Global Uptake of Variant Analysis Solution for Next-Generation Sequencing
Announcements at ESHG Meeting Highlight Adoption of Ingenuity Variant Analysis by Major European Centers
Redwood City, CA - June 10, 2013 - Ingenuity® Systems, a QIAGEN company (Nasdaq: QGEN, Frankfurt QIA) and a leading provider of biomedical information and analysis solutions, today announced that to date more than 2,500 users representing over 1,000 leading institutions worldwide - including Queen Mary, University of London and Rigshospitalet Copenhagen - have adopted the Ingenuity Variant AnalysisTM web-based solution.
Ingenuity Variant Analysis enables the analysis and interpretation of human sequencing data from large-scale whole genome, exome and targeted panel studies conducted with Next-Generation Sequencing (NGS) technologies. Identifying specific disease-causing variants from large-scale whole genome and exome studies, as well as from targeted panels, is difficult and time consuming due to the large number of variants within these data sets and the inherent complexity of creating associations within human biological systems. The Ingenuity Variant Analysis solution provides researchers a powerful web-based platform for identifying and interpreting variants derived from data generated by high-throughput DNA sequencing instruments.
"The biological interpretation and search for causal variants in NGS data are the critical bottlenecks in large-scale NGS studies to understand diseases," said Finn Cilius Nielsen, Professor, Center of Genomic Medicine, Rigshospitalet Copenhagen. "We have chosen Ingenuity Variant Analysis as our standard for interpreting variants from sequencing studies to rapidly identify high-impact variants from our large-scale disease patient cohort."
Ingenuity Variant Analysis is a web-based application that enables researchers to rapidly identify causal variants from human sequencing data, using known information about the biological effects of genomic variation. The application uses the accurate, curated biological content in the Ingenuity Knowledge Base, plus many additional sources of variant-level content, to help researchers studying genetics and disease biology quickly sift through millions of variants and identify causal variants based upon known relationships with pathways, genes, biological processes, and diseases.
"The issue we face today is not in our ability to sequence human genomes quickly and cost-effectively, but rather in the months or years it takes to make sense of the data we are creating," stated Charles Mein, Genome Centre Manager, Barts and The London, Queen Mary's School of Medicine and Density. "This bottleneck is alleviated with Variant Analysis, and by bundling the solution as part of our sequencing services, we are able to offer our researchers a complete sample-to-insight workflow."
The company will be demonstrating Ingenuity Variant Analysis at the European Society of Human Genetics (ESHG) meeting in Paris June 8-11 in exhibition stand #554, and at the European Symposium of Biopathology / Paris Biopathology Symposium meeting, June 13-14, where staff scientists will present on using Ingenuity Variant Analysis in the interpretation of breast cancer subtypes.
To learn more about Ingenuity Variant Analysis, see http://www.ingenuity.com/variants.
About Ingenuity® Systems
Ingenuity Systems, a QIAGEN company, is the global leading provider of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems in life science research and molecular diagnostics. Today, Ingenuity's solutions are used by tens of thousands of researchers and clinicians at hundreds of leading pharmaceutical, biotechnology, academic, diagnostic and clinical institutions worldwide.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA,RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2013, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at http://www.qiagen.com/.